Louise E Craig1,2, Sandy Middleton1, Helen Hamilton1, Fern Cudlip3, Victoria Swatzell4, Andrei V Alexandrov5, Elizabeth Lightbody6, Dame Caroline Watkins7, Sheeba Philip8, Dominique A Cadilhac9,10, Elizabeth McInnes1, Simeon Dale1, Anne W Alexandrov4,11. 1. Nursing Research Institute, St Vincent's Health AUS (Sydney) and Australian Catholic University, Sydney, New South Wales, Australia. 2. Centre for Research in Evidence-Based Practice (CREBP), Bond University, Robina, Queensland, Australia. 3. Stroke Team, Good Samaritan Comprehensive Stroke Center, San Jose, California, USA. 4. Mobile Stroke Unit, University of Tennessee Health Science Center at Memphis, Memphis, Tennessee, USA. 5. Department of Neurology, University of Tennessee Health Science Center at Memphis, Memphis, Tennessee, USA. 6. College of Health and Wellbeing, University of Central Lancashire, Preston, United Kingdom. 7. Faculty of Health and Wellbeing, University of Central Lancashire, Preston, United Kingdom. 8. East Lancashire Hospitals NHS Trust, Blackburn, United Kingdom. 9. Stroke and Ageing Research, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia. 10. Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia. 11. College of Medicine, Department of Neurology & College of Nursing, University of Tennessee Health Science Center at Memphis, Memphis, Tennessee, USA.
Abstract
BACKGROUND: Strict criteria for recombinant tissue plasminogen activator (rtPA) eligibility are stipulated on licences for use in ischaemic stroke; however, practitioners may also add non-standard rtPA criteria. We examined eligibility criteria variation in 3 English-speaking countries including use of non-standard criteria, in relation to rtPA treatment rates. METHODS: Surveys were mailed to 566 eligible hospitals in Australia (AUS), the UK, and the USA. Criteria were pre-classified as standard (approved indication and contraindications) or non-standard (approved warning or researcher "decoy"). Percentage for criterion selection was calculated/compared; linear regression was used to assess the association between use of non-standard criteria and rtPA treatment rates, and to identify factors associated with addition of non-standard criteria. RESULTS: Response rates were 74% AUS, 65% UK, and 68% USA; mean rtPA treatment rates were 8.7% AUS, 12.7% UK, and 8.7% USA. Median percentage of non-standard inclusions was 33% (all 3 countries) and included National Institutes of Health Stroke Scale (NIHSS) scores > 4, computed tomography (CT) angiography documented occlusion, and favourable CT perfusion. Median percentage of non-standard exclusions was 25% AUS, 28% UK, and 60% USA, and included depressed consciousness, NIHSS > 25, and use of antihypertensive infusions. No AUS or UK sites selected 100% of standard exclusions. CONCLUSIONS: Non-standard criteria for rtPA eligibility were evident in all three countries and could, in part, explain comparably low use of rtPA. Differences in the use of standard criteria may signify practitioner intolerance for those derived from original efficacy studies that are no longer relevant.
BACKGROUND: Strict criteria for recombinant tissue plasminogen activator (rtPA) eligibility are stipulated on licences for use in ischaemic stroke; however, practitioners may also add non-standard rtPA criteria. We examined eligibility criteria variation in 3 English-speaking countries including use of non-standard criteria, in relation to rtPA treatment rates. METHODS: Surveys were mailed to 566 eligible hospitals in Australia (AUS), the UK, and the USA. Criteria were pre-classified as standard (approved indication and contraindications) or non-standard (approved warning or researcher "decoy"). Percentage for criterion selection was calculated/compared; linear regression was used to assess the association between use of non-standard criteria and rtPA treatment rates, and to identify factors associated with addition of non-standard criteria. RESULTS: Response rates were 74% AUS, 65% UK, and 68% USA; mean rtPA treatment rates were 8.7% AUS, 12.7% UK, and 8.7% USA. Median percentage of non-standard inclusions was 33% (all 3 countries) and included National Institutes of Health Stroke Scale (NIHSS) scores > 4, computed tomography (CT) angiography documented occlusion, and favourable CT perfusion. Median percentage of non-standard exclusions was 25% AUS, 28% UK, and 60% USA, and included depressed consciousness, NIHSS > 25, and use of antihypertensive infusions. No AUS or UK sites selected 100% of standard exclusions. CONCLUSIONS: Non-standard criteria for rtPA eligibility were evident in all three countries and could, in part, explain comparably low use of rtPA. Differences in the use of standard criteria may signify practitioner intolerance for those derived from original efficacy studies that are no longer relevant.
Authors: Atte Meretoja; Jukka Putaala; Turgut Tatlisumak; Sari Atula; Ville Artto; Sami Curtze; Olli Häppölä; Perttu J Lindsberg; Satu Mustanoja; Katja Piironen; Janne Pitkäniemi; Kirsi Rantanen; Tiina Sairanen; Oili Salonen; Heli Silvennoinen; Lauri Soinne; Daniel Strbian; Marjaana Tiainen; Markku Kaste Journal: Stroke Date: 2010-06-10 Impact factor: 7.914
Authors: Georgios Tsivgoulis; Aristeidis H Katsanos; Dimitris Mavridis; Anne W Alexandrov; Georgios Magoufis; Adam Arthur; Valeria Caso; Peter D Schellinger; Andrei V Alexandrov Journal: Ther Adv Neurol Disord Date: 2016-12-01 Impact factor: 6.570
Authors: Kathleen L Bagot; Dominique A Cadilhac; Peter J Hand; Michelle Vu; Christopher F Bladin Journal: Lancet Date: 2016-08-20 Impact factor: 79.321
Authors: Salomeh Keyhani; Greg Arling; Linda S Williams; Joseph S Ross; Diana L Ordin; Jennifer Myers; Gary Tyndall; Bruce Vogel; Dawn M Bravata Journal: Med Care Date: 2012-01 Impact factor: 2.983
Authors: Nitin Goyal; Georgios Tsivgoulis; Ramin Zand; Vijay K Sharma; Kristian Barlinn; Shailesh Male; Aristeidis H Katsanos; Ulf Bodechtel; Sulaiman Iftikhar; Adam Arthur; Lucas Elijovich; Anne W Alexandrov; Andrei V Alexandrov Journal: Neurology Date: 2015-09-25 Impact factor: 9.910